Utilidad del biomarcador PIVKA II como herramienta dedetección temprana de hepatocarcinoma

Willinton  Eraso; Brandon Alexander  Gutiérrez; Jennifer Carolina  Gutiérrez; Carmen Cecilia  Almonacid

doi:10.22490/24629448.9972

Vol. 23 No. 44 (2025): 1.

Published 2025-07-01

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Article of Review (before OJS)

Utility of the PIVKA II biomarker as a tool for earlydetection of hepatocarcinoma

DOI: https://doi.org/10.22490/24629448.9972

Willinton Eraso Universidad Colegio Mayor de Cundinamarca

Brandon Alexander Gutiérrez Universidad Colegio Mayor de Cundinamarca

Jennifer Carolina Gutiérrez Universidad Colegio Mayor de Cundinamarca

Carmen Cecilia Almonacid Universidad Colegio Mayor de Cundinamarca

PDF (Spanish)

Abstract
References

Hepatocellular carcinoma is the most common liver neoplasm and one of the leading causes of cancer mortality worldwide. Early detection is crucial to improve prognoses and survival, yet most patients are diagnosed at advanced tumor stages, resulting in the loss of valuable treatment opportunities. Despite the standardized use of imaging such as biannual ultrasound and alpha-fetoprotein measurement, screening remains suboptimal. Therefore, PIVKA-II has been proposed as a clinically useful biomarker in early diagnosis, even in the context of negative alpha-fetoprotein measurement, with high sensitivity and specificity for detection of small tumors and high discriminatory ability for differentiating hepatocellular carcinoma of viral or metabolic etiology. PIVKA-II is an anomalous form of prothrombin, with absence of γ-carboxylation on one or more of its glutamic acid residues,altering its interaction with other factors of the coagulation cascade. This post-translational modification is favored by a decrease in the enzymatic activity of γ-glutamyl carboxylase in the context of the tumor microenvironment. Multiple controversies arise regarding the optimal cut-off values for screening, the most appropriate measurement methods and its diagnostic performance in isolation or in combination with other biomarkers.

keywords: PIVKA-II, Hepatocellular Carcinoma, Alpha-Fetoprotein, Tumor Biomarkers, Vitamin K Deficiency

Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(11):1295–307. DOI: 10.1080/17474124.2021.1991792

Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Współczesna Onkol. 2018;22(3):141–50. DOI: 10.5114/ wo.2018.78941

Shahini E, Pasculli G, Solimando AG, Tiribelli C, Cozzolongo R, Giannelli G. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. Int J Mol Sci. 2023;24(5):4286. DOI: 10.3390/ ijms24054286

Prieto Ortíz JE, Garzón Orjuela N, Sanchez Pardo S, Prieto Ortíz RG, Eslava Schmalbach JH. Hepatocarcinoma: experiencia de la vida real en un centro especializado de Bogotá, Colombia. Rev Colomb Gastroenterol. 2022;37(2):163–73. DOI: 10.22516/25007440.823

Gomez-Aldana A, Rosselli D. Hepatocellular carcinoma in Colombia 2017 – 2021. Ann Hepatol. 2023;28(2):100902. DOI: 10.1016/j.aohep.2023.100902

Mantilla Durán WA, Bonilla A, Borras M, Pérez JM, Guerra Villamizar J, Munévar I, et al. Características y desenlaces clínicos en pacientes con carcinoma hepatocelular (HCC) temprano o avanzado, tratados con quimioembolización (DEB-TACE) en una institución en Colombia. Rev Colomb Hematol Oncol. 2023;9(Supl):225–7. DOI: 10.51643/22562915.630

International Agency for Research on Cancer. Global Cancer Observatory [Internet]. 2022. Age-Standardized Rate (World) per 100 000, Incidence, Both sexes, in 2022

Villalba-López F, Sáenz-Mateos LF, Sánchez-Lorencio MI, De La Orden-García V, Alconchel-Gago F, Cascales-Campos PA, et al. Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma. Sci Rep. 2023;13(1):5621. DOI: 10.1038/s41598-023- 32879-9

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. The Lancet. 2022;400(10360):1345–62. DOI: 10.1016/S0140- 6736(22)01200-4

Ahn JC, Lee Y-T, Agopian VG, Zhu Y, You S, Tseng H-R, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10. DOI: 10.20517/2394-5079.2021.131

Lee J, Hwang J-H, Chun H, Woo W, Oh S, Choi J, et al. PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer. Int J Mol Sci. 2021;22(14):7614. DOI: 10.3390/ijms22147614

YanQ,SunY,AnR,LiuF,FangQ,WangZ,etal. Application and progress of the detection technologies in hepatocellular carcinoma. Genes Dis. 2023;10(5):1857–69. DOI: 10.1016/j.gendis.2022.04.003

Lapitan LDS, Pietrzak M, Krawczyk M, Malinowska E. Serum biomarkers and ultrasensitive biosensors for diagnosis of early-stage hepatocellular carcinoma. Sens Actuators B Chem. 2023;393:134209. DOI: 10.1016/j. snb.2023.134209

Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, et al. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel). 2021;13(10):2305. DOI: 10.3390/cancers13102305

ZhouZ,LiuQ,LiuJ,LiW,CaoS,XuJ,etal.Research progress of protein induced by vitamin K absence or antagonist II in liver transplantation for hepatocellular carcinoma. Heliyon. 2024;10(9):e30622. DOI: 10.1016/j. heliyon.2024.e30622

Molins Correa F, Serrano Rosa MA. Bases neurales de la aversión a las pérdidas en contextos económicos: revisión sistemática según las directrices PRISMA. Rev Neurol. 2019;68(02):47. DOI: 10.33588/rn.6802.2018276

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606. DOI: 10.1016/j.jhep.2022.08.021

Eraso, et al. Utilidad del biomarcador PIVKA II como herramienta de detección temprana de hepatocarcinoma

Cai Y, Xie K, Adeeb Alhmoud MN, Lan T, Wan H, Hu D, et al. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery. Cancer Med. 2023;12(17):17866–77. DOI: 10.1002/cam4.6422

Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567. DOI: 10.1016/j.esmoop.2023.101567

Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. DOI: 10.1186/s12885-021-08138-3

Tian S, Chen Y, Zhang Y, Xu X. Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2023;37(1). DOI: 10.1002/jcla.24823

Dong L, Qiu X, Gao F, Wang K, Xu X. Protein induced by vitamin K absence or antagonist II: Experience to date and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(6):189016. DOI: 10.1016/j. bbcan.2023.189016

Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses. 2021;13(7). DOI: 10.3390/v13071318

Guan M-C, Ouyang W, Liu S-Y, Sun L-Y, Chen W-Y, Tong X-M, et al. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. Hepatobiliary & Pancreatic Diseases International. 2022;21(6):559–68. DOI: 10.1016/j.hbpd.2022.05.003

Xu F, Zhang L, He W, Song D, Ji X, Shao J. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers. 2021;2021:1–9. DOI: 10.1155/2021/8868370

Degasperi E, Perbellini R, D’Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, et al. Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents. Aliment Pharmacol Ther. 2022;55(3):350–9. DOI: 10.1111/apt.16685

Suttichaimongkol T, Mitpracha M, Tangvoraphonkchai K, Sadeea P, Sawanyawisuth K, Sukeepaisarnjaroen W. PIVKA- II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients. J Circ Biomark. 2023;12:12–6. DOI: 10.33393/jcb.2023.2453

Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol. 2021;11. DOI: 10.3389/fonc.2021.726213

GeC,LuoM,GuoK,ZhuD,HanN,WangT,etal.Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: A large-scale real-world study. iLIVER. 2022;1(4):209–16. DOI: 10.1016/j. iliver.2022.11.003

Zhu W, Wang W, Zheng W, Chen X, Wang X, Xie J, et al. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study. Sci Rep. 2024;14(1):8416. DOI: 10.1038/s41598-024-59174-5

Honda T, Ichikawa T, Yamashima M, Yamamichi S, Koike M, Nakano Y, et al. PIVKA-II is associated with liver function, bone metabolism, and muscle function in patients with liver disease. Biomed Rep. 2023;20(1):2. DOI: 10.3892/ br.2023.1690

Farina A, Tartaglione S, Preziosi A, Mancini P, Angeloni A, Anastasi E. PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC. Int J Mol Sci. 2024;25(6). DOI: 10.3390/ijms25063498

Eraso W. [Internet]. 2024. Fisiopatología del CHC en relación a PIVKA-II [cited 2024 Nov 10]. Available from: https://app.biorender.com/profile/WillintonEB/templates/ 6808537be6f38bd5c34102d0

Jabor A, Kubíček Z, Čásenská J, Vacková T, Filová V, Franeková J. Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay. Pract Lab Med. 2024;39:e00389. DOI: 10.1016/j. plabm.2024.e00389

Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, et al. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. 2022;6(5):292–300. DOI: 10.1002/jgh3.12720

FUJIFILM Wako Pure Chemical Corporation. [Internet]. μTASWako PIVKA II For In Vitro Diagnostic Use [cited 2024 Nov 6]. Available from: https://diagnostic-wako. fujifilm.com/asia/products/hcc-risk-biomarkers/pivka-2. html

Phan TH, Chi Nguyen VT, Thi Pham TT, Nguyen V-C, Ho TD, Quynh Pham TM, et al. Circulating DNA Methylation Profile Improves the Accuracy of Serum Biomarkers for the Detection Of Nonmetastatic Hepatocellular Carcinoma. Future Oncology. 2022;18(39):4399–413. DOI: 10.2217/ fon-2022-1218

Ai Z, Zhao M, Han D, Chen K, Xiong D, Tang H. An “on- off” electrochemiluminescence immunosensor for PIVKA- II detection based on the dual quenching of CeO2–Au-g- C3N4 hybrids by Ag nanocubes-VB2. Biosens Bioelectron. 2021;179:113059. DOI: 10.1016/j.bios.2021.113059

Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, et al. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal. 2021;35(11):e24013. DOI: 10.1002/jcla.24013

Basile U, Miele L, Napodano C, Ciasca G, Gulli F, Pocino K, et al. The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: a pilot study. Eur Rev Med Pharmacol Sci. 2020;24(24):12675–85. DOI: 10.26355/eurrev_202012_24165

Liu Z, Wu M, Lin D, Li N. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa- fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. Journal of International Medical Research. 2020;48(2). DOI: 10.1177/0300060520902575

Loglio A, Iavarone M, Facchetti F, Di Paolo D, Perbellini R, Lunghi G, et al. The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy. Liver International. 2020;40(8):1987–96. DOI: 10.1111/liv.14475

Huang C, Xiao X, Zhou L, Chen F, Wang J, Hu X, et al. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC. J Clin Lab Anal. 2023;37(23–24):e24990. DOI: 10.1002/jcla.24990

Kim DY, Toan BN, Tan C-K, Hasan I, Setiawan L, Yu M-L, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023;29(2):277– 92. DOI: 10.3350/cmh.2022.0212

XingX,CaiL,OuyangJ,WangF,LiZ,LiuM,etal. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma. Nat Commun. 2023;14(1):8392. DOI: 10.1038/ s41467-023-44255-2

Malov SI, Malov IV, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, et al. Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C. Sovremennye tehnologii v medicine. 2021;13(1):27. DOI: 10.17691/stm2021.13.1.03

Ouyang W, Wang M-D, Guan M-C, Diao Y-K, Sun L-Y, Wang N-Y, et al. Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease. iLIVER. 2024;3(2):100098. DOI: 10.1016/j. iliver.2024.100098

Oikawa T, Yamada K, Tsubota A, Saeki C, Tago N, Nakagawa C, et al. Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma. Gastro Hep Adv. 2023;2(1):83– 95. DOI: 10.1016/j.gastha.2022.07.020

WangG,LuX,DuQ,ZhangG,WangD,WangQ,etal. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep. 2020;10(1):13519. DOI: 10.1038/s41598-020-70241-5

Omar MA, Omran MM, Farid K, Tabll AA, Shahein YE, Emran TM, et al. Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis. Biomedicines. 2023;11(7):1852. DOI: 10.3390/biomedicines11071852

Bhatti ABH, Naz K, Abbas G, Khan NY, Zia HH, Ahmed IN. Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2021;22(6):1731–6. DOI: 10.31557/ APJCP.2021.22.6.1731

Jang T-Y, Dai C-Y. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma. Medicine. 2022;101(39):e30936. DOI: 10.1097/MD.0000000000030936

Caviglia GP, Abate ML, Troshina G, Carucci P, Rolle E, Risso A, et al. Identification of the Best Cut-Off Value of PIVKA- II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development. Biology (Basel). 2023;12(1):94. DOI: 10.3390/biology12010094

TaoJ,ZhangW,YueH,ZhuG,WuW,GongW,etal. Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015–2018. Sci Rep. 2019;9(1):13948. DOI: 10.1038/s41598-019-50173-5

Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, et al. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina Clínica (English Edition). 2021;156(9):463.e1-463.e30. DOI: 10.1016/j.medcle.2020.09.004

Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–65. DOI: 10.1097/HEP.000 0000000000466

license

How to Cite

Eraso, W., Gutiérrez, B. A. ., Gutiérrez, J. C. ., & Almonacid, C. C. . (2025). Utility of the PIVKA II biomarker as a tool for earlydetection of hepatocarcinoma. NOVA Biomedical Sciences Journal, 23(44). https://doi.org/10.22490/24629448.9972

Download Citation

Almétricas

Metrics

Metrics Loading ...

Declaración de privacidad.

Utility of the PIVKA II biomarker as a tool for earlydetection of hepatocarcinoma

How to Cite